At Quibim, we understand the importance of protecting sensitive medical records throughout the process. 🔐 We guarantee privacy and security in healthcare data, beginning with the collection of imaging data from patient scans within #healthcare facilities. How? ⚙ By connecting local PACS with Quibim's cloud-based analysis tools and delivering an intuitive and efficient workflow, it streamlines the process of uploading and transmitting #data using SSL/HTTPS protocols. This ensures the utmost confidentiality of information. ✅ Your healthcare data stays protected throughout the process, consistently maintaining GDPR and HIPAA compliance. Find the full details here ⬇ https://bit.ly/47ZNdoD
Only this year, more than 280,000 Americans will be diagnosed with #prostatecancer, and as September unfolds, we unite to combat this health challenge that impacts lives all around the world 🌍. During National #ProstateCancerAwarenessMonth, we must come together to raise awareness about preventing and curing this disease. United, we have the potential to transform the lives of countless individuals and families. Echoing the words of the President of the United States of America: “To all those caring for loved ones with prostate cancer and all those facing it themselves, we stand with you”. https://bit.ly/44AaD0A
In the realm of oncology, biomarkers hold the key to personalized #patientcare. Discover radiomics, a groundbreaking method that extracts quantitative insights from medical images using advanced algorithms. Much like molecular diagnostics decode molecular signatures, radiomics unveils hidden patterns, shedding light on intricate biological processes. 🔍 Imagine the Possibilities: Can a patient benefit from immunotherapy or targeted treatments? Imaging-based predictions hold the answer. With imaging biomarker panels, predictive insights shape the future of #oncology as integrating them into #AI models elevates clinical precision, tailors treatment plans, and fosters drug development. This trajectory propels us toward a future where every patient receives a treatment that has been precisely designed for their unique journey. Read our latest blog to find out everything about it https://bit.ly/47TAN1m
In #prostatecancer, accurate risk assessment and early biochemical recurrence (BCR) detection are crucial. Given the significant roles of MRI and radiomics, it's essential to study localized PCa patients who undergo neoadjuvant therapy and radiotherapy. These insights highlight the promise of region-specific imaging profiles in pinpointing patients at increased risk of BCR and those with poor prognoses. These profiles demonstrate even greater predictive accuracy when combined with clinical #data. Imaging biomarkers promise to forecast BCR and assess risks up to ten years after diagnosis. Access our comprehensive scientific paper to delve deeper into the nuances and implications of this groundbreaking research. Stay updated with the latest advancements in #ImagingInnovations! https://bit.ly/44fSu8k Angel Luis Sánchez Iglesias, Virginia Morillo Macías, Alfonso Picó, 🔬Almudena Fuster Matanzo, PhD, Anna Nogué Infante, Fuensanta Bellvís Bataller, Marcos Domingo Pomar, Carlos Casillas Meléndez, Raúl Yebana Huertas, Carlos Ferrer Albiach
Radiologists regularly evaluate and label thousands of medical images with the aim of identifying whether a patient has potential #cancer lesions. However, as their average workload considerably increases, and given the complexity of certain clinical scenarios, unintentional misdiagnoses may occur. According to our Medical Advisor 🔬Almudena Fuster Matanzo, PhD, implementing #AI to medical imaging, can not only lighten the load for #radiologists, but can also assist in identifying pathological conditions much more quickly, encouraging early intervention. Furthermore, AI-driven algorithms applied to medical imaging may also facilitate patient’s follow-up and allow to predict important clinical outcomes. Using AI takes the subjectivity out of the equation and can help determine the best course of treatment for the patient. Providing personalized management, physicians can specifically target the illness, ensuring the right treatment, to the right patients at the right time.
Next September, our CEO Ángel Alberich-Bayarri will be presenting at #LSIEurope23 in Barcelona, and talking about how Quibim helps to identify candidates for clinical studies or patients more likely to respond to a drug, monitoring toxicity and adverse events through AI model. Thanks LSI - Life Science Intelligence™ for giving us this space!
🧠 Access to extensive real-world datasets is crucial to fully unlocking #AI's potential. Five forward-thinking EU projects are joining forces to develop large-scale big data infrastructures. These will drive the creation of ethically compliant and GDPR-aligned medical imaging platforms. Our latest paper gives an overview of this groundbreaking effort, highlighting both the challenges and the chosen solutions. We provide valuable insights and feedback to steer future work in this rapidly advancing field. Our goal is to aid in creating, validating, and implementing dependable and trustworthy AI models for addressing #cancercare. Please read all about it here: https://bit.ly/3rTKnRt
In today's competitive job market, companies are constantly looking for innovative ways to attract and withhold talent. In view of this backdrop, Quibim offers a wide range of benefits for its employees and fosters an empowering work environment. By exchanging ideas, sharing knowledge, and establishing meaningful relationships with their co-workers, #quibimers truly enjoy coming to the office. Because Quibim understands the value of delivering the best to its team, even with the possibility of working remotely, many of our employees prefer to work in the office. Read more about our inspiring workplace culture and find out why our team thrives in this environment in our latest blog post written by our Employer Branding & Talent Manager Silvia Soler Urbano. https://bit.ly/47EnPVl #beaquibimer
If one thing is certain, it's that #radiomics is the next big breakthrough in #oncology research and treatment. This relatively new subfield of '-omics', helps #lifesciences and healthcare organizations to move a step forward towards #precisionmedicine, by unlocking thousands of previously unattainable insights and information about tumors contained in medical imaging but imperceptible by the human eye. This approach in combination with #AI-driven algorithms has raised oncology research to a next level. Specialists can utilize radiomic data from #medicalimages to better understand how tumors or lesions respond to a specific therapy or to predict valuable #clinicaloutcomes, such as those related to patient’s progression and survival. The main goal is to enable better decision making at each stage of the cancer patient's journey, as personalization of #treatment generates the best outcomes for each patient. In Quibim we are committed to precision medicine, applying the latest AI technology to find out how radiomics contributes to improving each phase of patient journey.
It was an absolute privilege to engage in a thought-provoking conversation about the future of medicine and the transformative impact of #AI in healthcare with Dr. andres cervantes, Medical Oncologist and esteemed Chair of the ESMO - European Society for Medical Oncology. Our discussion delved into groundbreaking advancements in #precisionmedicine, where tailored treatments are improving #patientcare and outcomes. Dr. Cervantes' insights shed light on how cutting-edge technologies are taking this medical frontier forward. This dialogue reaffirmed our commitment at Quibim to explore AI's capabilities to drive #innovation and enhance #healthcare, to shape the future of medicine, making a positive impact on patient lives worldwide.
